Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02409589
Other study ID # 2015-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 2015
Est. completion date October 2015

Study information

Verified date April 2022
Source The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare a new intracavitary ECG guiding method for real-time positioning the tip of three-way valve type peripherally inserted central catheters versus conventional surface prediction length method in terms of single-time target rate.


Description:

The use of peripherally inserted central catheters (PICCs) has increased significantly for cancer patients receiving chemotherapy. For these patients, PICCs afford many advantages with regards to complications and treatment convenience. Current practice utilizes the estimated length of the catheter from puncture site to the junction of superior vena cava / right atrium (SVC-RA) for guiding tip placement. Next the catheter tip placement was confirmed by radiographic imaging prior to use of the line for administration of chemotherapy medications. In this case, the catheter is often mal-positioned and requires adjustment and repeat radiographic imaging in order to ensure proper placement, ideally at the SVC-RA junction. These potentially additional procedures are time-consuming and also expose patients, nurses and physicians to radiations. Intracavitary electrocardiogram with an electrode placed inside the catheter during insertion has shown identifiable changes in P-wave, which are sufficient to guide PICC tip placement. Moreover, less procedural time and radiation are expected. This study aims to demonstrate if this intracavitary electrocardiogram guided method is superior to conventional surface prediction length method in terms of single-time target rate of correct tip placement. In addition, we would like to investigate symptomatic thrombosis incidence and its risk factors after three-valve PICC implanted among patients with malignant tumors; to clarify procedure time used and cost of the new intracavitary ECG guiding method and to explore the maximal P-wave amplitude of intracavity ECG real-time positioning technology and its predictive factors.


Recruitment information / eligibility

Status Completed
Enrollment 1007
Est. completion date October 2015
Est. primary completion date June 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Patients with malignant tumors who will require periodical infusion of chemotherapy drugs using three-valve PICC; 2. Aged >18 to < 80 years old; 3. Baseline ECG records prior to PICC catheter showed normal P wave; 4. Agreed to participate in this study, and signed PICC informed consent. Exclusion Criteria: 5. Patients with heart diseases, such as valvular heart disease, atrial fibrillation, supraventricular tachycardia, pulmonary heart disease or having a pacemaker and post cardiac surgery which may affect P waves. 6. Patients unable to lie in the prostrate or semi-supine position.

Study Design


Related Conditions & MeSH terms

  • Intracavitary Electrocardiogram Guiding
  • Peripherally Inserted Central Catheter

Intervention

Device:
ECG
The ECG-guided PICC tip detection method will be used to identify catheter tip location during the procedural placement of the catheter. This method involves an ECG monitor which will be connected to the guidewire used for catheter placement. The changes in the ECG p-wave will guide correct PICC placement. An X-ray radiograph will be conducted to confirm the tip location after PICC placement.
Procedure:
Surface prediction length method
The method will estimate the length of the catheter from puncture site to the junction of superior vena cava / right atrium (SVC-RA) . Tip location is placed according to the estimated length but later on will be determinated by chest X-ray performed after the placement procedure. If the tip location is not at an ideal place, additional procedures and X-ray radiograph would be required in order to ensure proper tip location.

Locations

Country Name City State
China Jiangsu Cancer Hospital Nanjing Jiangsu
China Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School Nanjing Jiangsu
China Nanjing General Hospital of Nanjing Military Command Nanjing Jiangsu
China Nanjing Hospital Affiliated to Nanjing Medical University Nanjing Jiangsu
China The 2nd Affliated Hospital of Nanjing Medical University Nanjing Jiangsu
China The First Affiliated Hospital of Soochow University Suzhou Jiangsu
China The Second Affiliated Hospital of Soochow University Suzhou Jiangsu
China People's Hospital Affiliated to Jiangsu University Zhenjiang Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Yuan Ling

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Single-time target rate Less than 24 hours
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03230357 - Research on the Localization Accuracy of PICC Guided by EDUG in Real World N/A
Completed NCT03299868 - Comparison Between Initial Routine PICC and General IV Access in Terminally Ill Cancer Patients Phase 2
Completed NCT04263649 - Prospective Observational Study of the Power PICC Family of Devices and Accessories
Recruiting NCT05278507 - Comparing Arrow PICC Catheters w/ Arrowga+rd Blue Advanced Protection Performance and Safety to Unprotected PICC's N/A